The week in pharma: action, reaction and insight – week to August 9, 2024

11 August 2024

By Barbara Obstoj-Cardwell. Edito

Last week’s news included second quarter financial results from BioNTech, the German mRNA biotech behind the successful covid vaccine Comirnaty, along with an update on its R&D pipeline. On the deal-making front, US biotech Equillium announced progress for its graft-versus-host disease drug itolizumab that is partnered with Japan’s Ono Pharmaceutical. Also, US gene editing firm Sangamo signed a licensing deal with Roche subsidiary Genentech that could earn it more than $2 billion. M&A news saw US firm Recursion enter a merger agreement with the UK’s Exscientia. Eli Lilly reported second quarter financial that beat expectations, driven by the performances of its new diabetes and obesity drugs.

Third Bridge shares insights on BioNTech

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK